MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

83.59
+4.68
+5.93%
Closed 19:55 06/23 EDT
OPEN
80.01
PREV CLOSE
78.91
HIGH
84.99
LOW
79.65
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
92.00
52 WEEK LOW
16.54
MARKET CAP
5.70B
P/E (TTM)
-34.0225
1D
5D
1M
3M
1Y
5Y
Expert Ratings For Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago
Benzinga · 17h ago
Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $85
Baird analyst Madhu Kumar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $60 to $85.
Benzinga · 21h ago
Jefferies Adjusts Intellia Therapeutics' Price Target to $109 From $83, Reiterates Buy Rating
MT Newswires · 1d ago
--Baird Adjusts Intellia Therapeutics' Price Target to $85 From $60, Maintains Neutral Rating
MT Newswires · 1d ago
JMP Securities Adjusts Intellia Therapeutics' Price Target to $88 From $80, Maintains Market Outperform Rating
MT Newswires · 1d ago
Sector Update: Financial Stocks Drifting Higher Late in Tuesday Trading
MT Newswires · 1d ago
Sector Update: Financial Stocks Back Near Even, Recovering From Prior Declines
MT Newswires · 1d ago
Blackstone and Intellia in agreement to launch new CAR T-cell company
Delmaine Donson/E+ via Getty Images Blackstone (BX) has committed $250M to launch a new autologous and allogeneic universal chimeric antigen receptor ((CAR)) T-cell therapy company in partnership with Intellia Therapeutics
Seekingalpha · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTLA. Analyze the recent business situations of Intellia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTLA stock price target is 91.25 with a high estimate of 115.00 and a low estimate of 73.00.
EPS
Institutional Holdings
Institutions: 321
Institutional Holdings: 66.35M
% Owned: 97.35%
Shares Outstanding: 68.15M
TypeInstitutionsShares
Increased
107
7.00M
New
55
2.90M
Decreased
60
6.40M
Sold Out
40
1.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.36%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Non-Executive Chairman/Independent Director
Frank Verwiel
President/Chief Executive Officer/Director
John Leonard
Chief Financial Officer/Executive Vice President/Treasurer
Glenn Goddard
Chief Operating Officer/Executive Vice President
Andrew Schiermeier
Executive Vice President/Chief Scientific Officer
Laura Sepp-Lorenzino
Executive Vice President/General Counsel
Jose Rivera
Independent Director
Fred Cohen
Executive Vice President
David Lebwohl
Independent Director
Frederick Cohen
Independent Director
John Crowley
Independent Director
Caroline Dorsa
Independent Director
Jean-Francois Formela
Independent Director
Jesse Goodman
Independent Director
Georgia Keresty
No Data
About NTLA
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.